HK Stock Market Move | Shanghai Fosun Pharmaceutical (02196) rose by more than 5%, with a year-on-year increase in net profit of 21.69% and nearly a 30% increase in revenue from innovative drugs.

Shanghai Fosun Pharmaceutical (02196) rose by more than 5%, as of press time, it increased by 5.54% to 19.24 Hong Kong dollars, with a turnover of 197.755 million Hong Kong dollars. On the news front, on the evening of March 24, Shanghai Fosun Pharmaceutical released its 2025 annual performance. The group achieved operating income of 41.662 billion yuan (same unit), a year-on-year increase of 1.45%; net profit attributable to shareholders of the listed company was 3.371 billion yuan, a year-on-year increase of 21.69%; basic earnings per share were 1.27 yuan, and a cash dividend of 3.90 yuan (pre-tax) per 10 shares is proposed. In addition, the group's net cash flow from operating activities was 5.213 billion yuan, a year-on-year increase of 16.45%. During the reporting period, the group's innovative drugs achieved revenue of 9.893 billion yuan, a year-on-year increase of 29.59%, accounting for 33.16% of the pharmaceutical business revenue, an increase of 6.77 percentage points from the previous year. Among them, core products such as Peking, Aokangze, and Yikaida all achieved growth rates of over 30%, while products like Hanlikang, Hanquinu, and Hanszhuang maintained stable revenue growth.